行情

SESN

SESN

Sesen Bio, Inc.
NASDAQ

实时行情|Nasdaq Last Sale

1.050
+0.030
+2.94%
盘后: 1.020 -0.03 -2.86% 19:42 08/13 EDT
开盘
1.030
昨收
1.020
最高
1.060
最低
1.010
成交量
72.03万
成交额
--
52周最高
1.540
52周最低
0.3700
市值
1.23亿
市盈率(TTM)
-1.2931
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SESN价格均价为3.417,最高价位5.00,最低价为2.250。

EPS

SESN 新闻

更多
Sesen Bio shares are trading lower after the company reported worse-than-expected Q2 EPS results. UPDATE: Shares have reversed since then.
Benzinga · 3天前
Sesen Bio Q2 EPS $(0.24) Misses $(0.09) Estimate
Sesen Bio (NASDAQ:SESN) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.09) by 166.67 percent. This is a 64.18 percent increase over losses of $(0.67) per share from the
Benzinga · 3天前
Sesen Bio Reports Second Quarter 2020 Financial Results and Business Update
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the second quarter ended June 30, 2020. The Company also provided an update
Business Wire · 3天前
Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference
August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity 40th Annual
Business Wire · 08/05 20:15
Sesen Bio inks licensing deal for Vicineum
Seeking Alpha · 07/31 12:35
AAPL, FB among premarket gainers
Seeking Alpha · 07/31 12:26
Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu Pharmaceutical, a leading vertically integrated pharmaceutical company in China specializing in the manu
Business Wire · 07/31 11:30
Sesen Bio to Host Conference Call to Provide OUS Business Update
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Friday, July 31, 2020 at 8:00
Business Wire · 07/30 12:00

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

SESN 简况

Sesen Bio, Inc.(原名:Eleven Biotherapeutics, Inc.)是一家提供靶向蛋白疗法(TPT)平台的后期临床公司。该公司专注于开发治疗癌症的抗体药物偶联物(ADC)疗法。该公司的产品包括Vicinium、结合检查点抑制剂的Vicinium、durvalumab和VB6-845d。该公司的先导计划Vicinium是一种处于第III期开发的治疗非肌层浸润性膀胱癌(NMIBC)的融合蛋白。Vicinium靶向肿瘤细胞表面上的上皮细胞粘附分子(EpCAM)抗原,以将有效的细胞毒素假单胞菌外毒素A(ETA)直接递送至癌细胞。
展开

微牛提供Sesen Bio Inc(NASDAQ-SESN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SESN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SESN股票基本功能。